How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How would you manage a patient who presents with hair loss that began after they started a GLP-1 inhibitor?

In biopsy-confirmed F2 MASH with a lean BMI, what phenotype features (e.g., visceral adiposity, worsening glycemia/prediabetes, atherogenic dyslipidemia) most strongly push you toward a GLP-1 receptor agonist first versus a thyroid hormone receptor-beta agonist first versus upfront combination therapy?

When patients with MASLD have major metabolic improvement on modern anti-obesity/antidiabetic therapies, how do you interpret changes in NITs over time—do you re-stage prognosis based on updated values, and what magnitude/duration of change is sufficient to de-escalate or escalate liver- specific surveillance?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.